Sitomet ER Tablet 50 mg + 1000 mg is a fixed-dose extended-release combination of Sitagliptin and Metformin Hydrochloride for the management of type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and lowers glucagon levels, while Metformin ER reduces hepatic glucose production and improves insulin sensitivity.

The extended-release formulation allows for once-daily dosing, improving patient adherence and minimizing gastrointestinal side effects commonly associated with standard Metformin tablets. Sitomet ER is ideal for patients who require dual therapy for better blood sugar control when diet, exercise, or monotherapy is insufficient.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Sitagliptin 50 mg
• Metformin Hydrochloride 1000 mg (extended-release)

Mechanism of Action

Sitagliptin:

• Inhibits DPP-4 enzyme, increasing incretin hormone levels (GLP-1, GIP)
• Enhances insulin release post-meals and suppresses glucagon production, lowering blood glucose

Metformin ER:

• Reduces hepatic glucose output
• Improves peripheral glucose uptake, enhancing insulin sensitivity
• Delays intestinal glucose absorption, contributing to more stable glucose levels

Together, the combination provides complementary dual action to optimize glycemic control with reduced side effects.

Indications

Sitomet ER Tablet is indicated for:

• Adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
• Patients requiring dual therapy to manage fasting and postprandial glucose
• Long-term management to reduce the risk of diabetes-related complications

Dosage & Administration

• Recommended dose: 1 tablet once daily with the main meal
• Swallow the tablet whole; do not crush or chew
• Take with food to reduce gastrointestinal discomfort
• Dose adjustment may be necessary for patients with renal or hepatic impairment
• Regular monitoring of blood glucose, HbA1c, and renal function is advised
• Maintain diet and exercise as prescribed

Benefits

• Once-daily extended-release formulation for convenience and adherence
• Dual-action therapy addresses both insulin secretion and insulin resistance
• Effective control of fasting and postprandial blood sugar
• Reduced gastrointestinal side effects compared to standard Metformin
• Supports long-term glycemic control and lowers risk of diabetes complications

Possible Side Effects

Common side effects:

• Mild nausea, diarrhea, or abdominal discomfort
• Headache
• Dizziness

Rare but serious side effects:

• Lactic acidosis (associated with Metformin, particularly in renal impairment)
• Allergic reactions (rash, swelling, or itching)
• Hypoglycemia (rare when used alone, higher risk with additional antidiabetic medications)

Precautions & Warnings

• Avoid in patients with severe renal or hepatic impairment
• Not for use in type 1 diabetes or diabetic ketoacidosis
• Monitor kidney function regularly due to Metformin content
• Exercise caution during acute illness, dehydration, or excessive alcohol intake
• Discontinue immediately if symptoms of lactic acidosis appear
• Inform your doctor about all other medications being taken

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store at 20–25°C in a dry, cool place
• Keep in original packaging until use
• Protect from heat, moisture, and direct sunlight
• Keep out of reach of children

Conclusion

Sitomet ER Tablet 50 mg + 1000 mg (Sitagliptin + Metformin Hydrochloride) offers effective once-daily dual-action therapy for type 2 diabetes mellitus. Its combination of enhanced insulin secretion and improved insulin sensitivity ensures stable blood sugar control, better adherence, and long-term management of diabetes with reduced gastrointestinal side effects.